<DOC>
	<DOC>NCT00945386</DOC>
	<brief_summary>Pediatric patients, during their illness often treated with furosemide (Lasix) continuous drip, often, with dosages above 4-6mg/kg/day (the recommended dose). This study will monitor hearing status of these children prior to their therapy with furosemide, during this therapy and after.</brief_summary>
	<brief_title>The Effect of Continuous, Various Doses of Furosemide Drip on Hearing as Measured by Acoustic Emission</brief_title>
	<detailed_description>This study will record hearing status, by acoustic emission, of critically ill children, treated with different dosages of furosemide drip. Acoustic emission test will be done prior to therapy and q48 hours during their course of treatment with furosemide drip. Dosage of furosemide drip, boluses and other relevant medications (i.e - vancomycin, muscular relaxants, aminoglycosides etc) will be recorded.</detailed_description>
	<mesh_term>Furosemide</mesh_term>
	<criteria>All children admitted to Pediatric ICU who are treated with furosemide continuous drip. Children with known hearing abnormalities prior to treatment.</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>children</keyword>
	<keyword>critically ill</keyword>
	<keyword>furosemide</keyword>
	<keyword>acoustic emission</keyword>
</DOC>